{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:03:20Z","timestamp":1790697800098,"version":"4.1.0"},"reference-count":75,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>To review new advances in inclusion body myositis (IBM) and discuss them in light of current knowledge on diagnosis, pathomechanisms, and treatment perspectives.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>IBM is a treatment refractory inflammatory myopathy in middle-aged patients that leads to a slow, relentlessly progressive muscle weakness, and atrophy. Recent data collections suggest that mortality in IBM patients is somewhat elevated compared with the general population. One major risk factor for death is severe dysphagia, which can now be determined by a novel real-time MRI technique. Recently, proposed diagnostic criteria with a combination of clinical and histopathological features have improved sensitivity and specificity. cytosolic 5\u2019-nucleotidase 1A antibodies have been characterized in IBM patients and their pathophysiologic role has recently been studied. New inflammatory pathomechanisms have been identified in IBM muscle and may help to design novel treatment strategies. A broad spectrum of immunosuppressive and immunomodulatory trials have been conducted, but \u2013 so far\u2013 no effective treatment is available. Current therapeutic attempts aim to block the myostatin pathway or restore the protein homeostasis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The expanding knowledge of the complex disease, the refinement of diagnostic criteria, and developments in diagnostic procedures are expected to foster the much needed design of new treatment approaches for future clinical trials.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000436","type":"journal-article","created":{"date-parts":[[2017,8,20]],"date-time":"2017-08-20T02:34:16Z","timestamp":1503196456000},"page":"632-638","source":"Crossref","is-referenced-by-count":41,"title":["Inclusion body myositis: advancements in diagnosis, pathomechanisms, and treatment"],"prefix":"10.1097","volume":"29","author":[{"given":"Karsten","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1212\/WNL.55.9.1385","article-title":"Epidemiology of inclusion body myositis in the Netherlands: a nationwide study","volume":"55","author":"Badrising","year":"2000","journal-title":"Neurology"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.jocn.2008.01.011","article-title":"Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis","volume":"15","author":"Needham","year":"2008","journal-title":"J Clin Neurosci"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"672-e41","DOI":"10.1111\/ene.12627","article-title":"High prevalence of inclusion body myositis in Norway; a population-based clinical epidemiology study","volume":"22","author":"Dobloug","year":"2015","journal-title":"Eur J Neurol"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3233\/JND-160198","article-title":"A systematic review and meta-analysis of prevalence studies of sporadic inclusion body myositis","volume":"4","author":"Callan","year":"2017","journal-title":"J Neuromuscul Dis"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1093\/brain\/awr213","article-title":"Long-term observational study of sporadic inclusion body myositis","volume":"134","author":"Benveniste","year":"2011","journal-title":"Brain"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1093\/brain\/awr217","article-title":"A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities","volume":"134","author":"Cox","year":"2011","journal-title":"Brain"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3233\/JND-150138","article-title":"Mortality and causes of death in patients with sporadic inclusion body myositis: survey study based on the clinical experience of specialists in Australia, Europe and the USA","volume":"3","author":"Price","year":"2016","journal-title":"J Neuromuscul Dis"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.semarthrit.2015.06.005","article-title":"Survival and cancer risk in an unselected and complete Norwegian idiopathic inflammatory myopathy cohort","volume":"45","author":"Dobloug","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.clinph.2015.12.011","article-title":"Sporadic inclusion body myositis: a review of recent clinical advances and current approaches to diagnosis and treatment","volume":"127","author":"Needham","year":"2016","journal-title":"Clin Neurophysiol"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1212\/WNL.0000000000003337","article-title":"Evaluation of dysphagia by novel real-time MRI","volume":"87","author":"Olthoff","year":"2016","journal-title":"Neurology"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00415-009-5229-9","article-title":"Detecting dysphagia in inclusion body myositis","volume":"256","author":"Cox","year":"2009","journal-title":"J Neurol"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10072-011-0814-y","article-title":"A dysphagia study in patients with sporadic inclusion body myositis (s-IBM)","volume":"33","author":"Murata","year":"2012","journal-title":"Neurological Sci"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/0003489414525588","article-title":"Dysphagia due to inclusion body myositis: case presentation and review of the literature","volume":"123","author":"Ko","year":"2014","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ncl.2014.04.001","article-title":"Inclusion body myositis","volume":"32","author":"Dimachkie","year":"2014","journal-title":"Neurol Clin"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0016-5085(00)70137-5","article-title":"Development and validation of a self-report symptom inventory to assess the severity of oral-pharyngeal dysphagia","volume":"118","author":"Wallace","year":"2000","journal-title":"Gastroenterology"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3233\/JPD-150687","article-title":"Multimodal swallowing evaluation with high-resolution manometry reveals subtle swallowing changes in early and mid-stage Parkinson disease","volume":"6","author":"Jones","year":"2016","journal-title":"J Parkinsons Dis"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s00455-009-9245-9","article-title":"The impact of dysphagia on quality of life in ageing and Parkinson's disease as measured by the swallowing quality of life (SWAL-QOL) questionnaire","volume":"25","author":"Leow","year":"2010","journal-title":"Dysphagia"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/joor.12019","article-title":"Oropharyngeal dysphagia in amyotrophic lateral sclerosis alters quality of life","volume":"40","author":"Paris","year":"2013","journal-title":"J Oral Rehabil"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann Neurol"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1212\/01.wnl.0000277527.69388.fe","article-title":"Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM","volume":"70","author":"Chahin","year":"2008","journal-title":"Neurology"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"e004552","DOI":"10.1136\/bmjopen-2013-004552","article-title":"A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis","volume":"4","author":"Brady","year":"2014","journal-title":"BMJ Open"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.nmd.2013.08.007","article-title":"188th ENMC international workshop: inclusion body myositis, 2-4 December 2011, Naarden, The Netherlands","volume":"23","author":"Rose","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1212\/WNL.0000000000000642","article-title":"Evaluation and construction of diagnostic criteria for inclusion body myositis","volume":"83","author":"Lloyd","year":"2014","journal-title":"Neurology"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/mus.25036","article-title":"A protocol to develop clinical guidelines for inclusion-body myositis","volume":"53","author":"Jones","year":"2016","journal-title":"Muscle Nerve"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"e20266","DOI":"10.1371\/journal.pone.0020266","article-title":"Autoantibodies against a 43 KDa muscle protein in inclusion body myositis","volume":"6","author":"Salajegheh","year":"2011","journal-title":"PLoS One"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.23822","article-title":"Autoantibodies to cytosolic 5\u2019-nucleotidase 1A in inclusion body myositis","volume":"73","author":"Pluk","year":"2013","journal-title":"Ann Neurol"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.23840","article-title":"Cytosolic 5\u2019-nucleotidase 1A autoimmunity in sporadic inclusion body myositis","volume":"73","author":"Larman","year":"2013","journal-title":"Ann Neurol"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/acr.22600","article-title":"Cytosolic 5\u2019-nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases","volume":"68","author":"Lloyd","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/annrheumdis-2014-206691","article-title":"Disease specificity of autoantibodies to cytosolic 5\u2019-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases","volume":"75","author":"Herbert","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/annrheumdis-2016-210282","article-title":"Cytosolic 5\u2019-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis","volume":"76","author":"Lilleker","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.24919","article-title":"Pathomechanisms of anticytosolic 5\u2019-nucleotidase 1A autoantibodies in sporadic inclusion body myositis","volume":"81","author":"Tawara","year":"2017","journal-title":"Ann Neurol"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jocn.2014.09.012","article-title":"Inclusion body myositis: a review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches","volume":"22","author":"Mastaglia","year":"2015","journal-title":"J Clin Neurosci"},{"key":"R33-20230829","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/NEN.0b013e31826183c8","article-title":"Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis","volume":"71","author":"Askanas","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11926-010-0102-5","article-title":"Theories of the pathogenesis of inclusion body myositis","volume":"12","author":"Greenberg","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1586\/1744666X.2013.842467","article-title":"Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives","volume":"9","author":"Schmidt","year":"2013","journal-title":"Expert Rev Clin Immunol"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/acn3.419","article-title":"Immune and myodegenerative pathomechanisms in inclusion body myositis","volume":"4","author":"Keller","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/brain\/aws046","article-title":"Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1\u03b2-induced accumulation of \u03b2-amyloid and cell death","volume":"135","author":"Schmidt","year":"2012","journal-title":"Brain"},{"key":"R38-20230829","doi-asserted-by":"crossref","first-page":"5470831","DOI":"10.1155\/2017\/5470831","article-title":"IL-1\u03b2-induced accumulation of amyloid: macroautophagy in skeletal muscle depends on ERK","volume":"2017","author":"Schmidt","year":"2017","journal-title":"Mediators Inflamm"},{"key":"R39-20230829","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s13295-010-0010-1","article-title":"Of amyloid and inflammation: causes of chronic muscle disease","volume":"1","author":"Schmidt","year":"2010","journal-title":"e-Neuroforum"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1212\/WNL.0000000000002295","article-title":"Viruses in IBM: hit-and-run, hide and persist, or irrelevant?","volume":"86","author":"Dalakas","year":"2016","journal-title":"Neurology"},{"key":"R41-20230829","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1212\/WNL.0000000000002291","article-title":"Hepatitis C virus infection in inclusion body myositis: a case-control study","volume":"86","author":"Uruha","year":"2016","journal-title":"Neurology"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/ana.21103","article-title":"Inclusion body myositis with human immunodeficiency virus infection: four cases with clonal expansion of viral-specific T cells","volume":"61","author":"Dalakas","year":"2007","journal-title":"Ann Neurol"},{"key":"R43-20230829","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1212\/WNL.0000000000003821","article-title":"Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients","volume":"88","author":"Lloyd","year":"2017","journal-title":"Neurology"},{"key":"R44-20230829","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/ana.21115","article-title":"Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis","volume":"61","author":"L\u00fcnemann","year":"2007","journal-title":"Ann Neurol"},{"key":"R45-20230829","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2012.12.011","article-title":"TNF-\u03b1 upregulates macroautophagic processing of APP\/\u03b2-amyloid in a human rhabdomyosarcoma cell line","volume":"325","author":"Keller","year":"2013","journal-title":"J Neurol Sci"},{"key":"R46-20230829","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1074\/jbc.M110.159392","article-title":"TNF-alpha induces macroautophagy and regulates MHC class II expression in human skeletal muscle cells","volume":"286","author":"Keller","year":"2011","journal-title":"J Biol Chem"},{"key":"R47-20230829","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.24847","article-title":"Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis","volume":"81","author":"Guttsches","year":"2017","journal-title":"Ann Neurol"},{"key":"R48-20230829","doi-asserted-by":"crossref","first-page":"218.e1","DOI":"10.1016\/j.neurobiolaging.2016.07.024","article-title":"Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis","volume":"47","author":"Gang","year":"2016","journal-title":"Neurobiol Aging"},{"key":"R49-20230829","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s004150050005","article-title":"High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study","volume":"247","author":"Walter","year":"2000","journal-title":"J Neurol"},{"key":"R50-20230829","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"key":"R51-20230829","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/ana.10121","article-title":"Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo","volume":"51","author":"Badrising","year":"2002","journal-title":"Ann Neurol"},{"key":"R52-20230829","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1212\/01.WNL.0000134675.98525.79","article-title":"Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis","volume":"63","year":"2004","journal-title":"Neurology"},{"issue":"(2 Suppl 1)","key":"R53-20230829","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1212\/01.wnl.0000192258.32408.54","article-title":"Pilot trial of etanercept in the treatment of inclusion-body myositis","volume":"66","author":"Barohn","year":"2006","journal-title":"Neurology"},{"key":"R54-20230829","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jns.2013.08.007","article-title":"The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study","volume":"334","author":"Kosmidis","year":"2013","journal-title":"J Neurol Sci"},{"key":"R55-20230829","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/brain\/awp104","article-title":"Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis","volume":"132","author":"Dalakas","year":"2009","journal-title":"Brain"},{"key":"R56-20230829","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12883-016-0568-5","article-title":"Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM","volume":"16","author":"Schmidt","year":"2016","journal-title":"BMC Neurol"},{"key":"R57-20230829","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1002\/art.37692","article-title":"Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and \u03b2-amyloid in the muscle","volume":"64","author":"Zsch\u00fcntzsch","year":"2012","journal-title":"Arthr Rheumatol"},{"key":"R58-20230829","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000441490","article-title":"Subcutaneous immunoglobulin use in inclusion body myositis: a review of 6 cases","volume":"7","author":"Cherin","year":"2015","journal-title":"Case Rep Neurol"},{"key":"R59-20230829","article-title":"Inclusion body myositis treated with intravenous immunoglobulin: a long-term study (abstract)","volume":"84","author":"Murata","year":"2015","journal-title":"Neurology"},{"key":"R60-20230829","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11926-013-0329-z","article-title":"Update on treatment of inclusion body myositis","volume":"15","author":"Breithaupt","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"R61-20230829","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1212\/WNL.58.7.1081","article-title":"A pilot randomized trial of oxandrolone in inclusion body myositis","volume":"58","author":"Rutkove","year":"2002","journal-title":"Neurology"},{"key":"R62-20230829","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10072-011-0657-6","article-title":"Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis","volume":"32","author":"Sancricca","year":"2011","journal-title":"Neurol Sci"},{"key":"R63-20230829","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mus.21059","article-title":"Arimoclomol at dosages up to 300 mg\/day is well tolerated and safe in amyotrophic lateral sclerosis","volume":"38","author":"Cudkowicz","year":"2008","journal-title":"Muscle Nerve"},{"key":"R64-20230829","doi-asserted-by":"crossref","first-page":"331ra41","DOI":"10.1126\/scitranslmed.aad4583","article-title":"Targeting protein homeostasis in sporadic inclusion body myositis","volume":"8","author":"Ahmed","year":"2016","journal-title":"Sci Transl Med"},{"key":"R65-20230829","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/nan.12384","article-title":"Sporadic inclusion body myositis: a myodegenerative disease or an inflammatory myopathy","volume":"43","author":"Weihl","year":"2017","journal-title":"Neuropathol Appl Neurobiol"},{"key":"R66-20230829","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1517\/21678707.2014.966688","article-title":"Treatment strategies for inclusion body myositis","volume":"2","author":"Breithaupt","year":"2014","journal-title":"Expert Opin Orphan Drugs"},{"key":"R67-20230829","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1128\/MCB.01307-13","article-title":"An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy","volume":"34","author":"Lach-Trifilieff","year":"2014","journal-title":"Mol Cell Biol"},{"key":"R68-20230829","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1212\/WNL.0000000000001070","article-title":"Treatment of sporadic inclusion body myositis with bimagrumab","volume":"83","author":"Amato","year":"2014","journal-title":"Neurology"},{"key":"R69-20230829","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ymthe.2017.02.015","article-title":"Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes","volume":"25","author":"Mendell","year":"2017","journal-title":"Mol Ther"},{"key":"R70-20230829","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/PHM.0b013e31818a50e2","article-title":"Dysphagia in inclusion body myositis: clinical features, management, and clinical outcome","volume":"87","author":"Oh","year":"2008","journal-title":"Am J Phys Med Rehabil"},{"key":"R71-20230829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/CCRep.S10200","article-title":"Balloon dilation in sporadic inclusion body myositis patients with dysphagia","volume":"6","author":"Murata","year":"2013","journal-title":"Clin Med Insights Case Rep"},{"key":"R72-20230829","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00455-011-9384-7","article-title":"Pharyngeal dysphagia in inflammatory muscle diseases resulting from impaired suprahyoid musculature","volume":"27","author":"Langdon","year":"2012","journal-title":"Dysphagia"},{"key":"R73-20230829","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1155\/2004\/360537","article-title":"Injection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis","volume":"18","author":"Liu","year":"2004","journal-title":"Can J Gastroenterol"},{"key":"R74-20230829","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1212\/WNL.58.2.326","article-title":"Intravenous immunoglobulin for dysphagia of inclusion body myositis","volume":"58","author":"Cherin","year":"2002","journal-title":"Neurology"},{"key":"R75-20230829","first-page":"CD004303","article-title":"Interventions for dysphagia in long-term, progressive muscle disease","volume":"2","author":"Jones","year":"2016","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201711000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T06:36:45Z","timestamp":1693291005000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201711000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":75,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000436","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}